GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392:1789–1858. doi: 10.1016/S0140-6736(18)32279-7
Xie Y, et al. Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int 2018; 94:567–581. doi: 10.1016/j.kint.2018.04.011
Tuttle KR, et al. Clinical characteristics of and risk factors for chronic kidney disease among adults and children: An analysis of the CURE-CKD registry. JAMA Netw Open 2019; 2:e1918169. doi: 10.1001/jamanetworkopen.2019.18169
Perkovic V, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:2295–2306. doi: 10.1056/NEJMoa1811744
Heerspink HJL, et al., for the DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383:1436–1446. doi: 10.1056/NEJMoa2024816
Bakris GL, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020; 383:2219–2229. doi: 10.1056/NEJMoa2025845